for its vesicular localization and exocytosis. External application of ␣ -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and kainate (KA) induced vesicular exocytosis and release of sPLA 2 -IIA. UBP 302, a GluR5-specific KA receptor antagonist, abolished the effect of KA, confirming the role of KA receptors in mediating sPLA 2 -IIA secretion. Moreover, KA-induced sPLA 2 -IIA secretion is dependent on Ca 2+ and protein kinase C. Together, these findings provide evidence of a link between glutamate receptors and regulated sPLA 2 secretion in neurons that may play an important role in synaptic plasticity, pain transmission and neurodegenerative diseases.
Introduction
Phospholipases A 2 (PLA 2 ) are lipolytic enzymes that cleave the sn -2-acyl ester linkage of glycerophospholipid to liberate a free fatty acid and lysophospholipid [1] . The secretory type of mammalian PLA 2 (sPLA 2 ) has a low molecular weight of 13-19 kDa and is classified into sev-eral subtypes, sPLA 2 -IB, -IIA, -IIC, -IID, -IIE, -IIF, -III, -V, -X, -XIIA and -XIIB based mainly on the position of cysteine residues [2, 3] . Many sPLA 2 isoforms contain a signal peptide essential for their secretion. sPLA 2 -IIA, -IIC, -IID, -IIE, -IIF and -V are clustered on the same chromosome locus (1p34-p36) [4] . sPLA 2 -IB, -IIA, -IIC, -IIE, -III, -V and -X are found in the central nervous system (CNS) [5] [6] [7] . Relatively high levels of sPLA 2 activity are detected in the hippocampus, medulla oblongata and pons [8] . PLA 2 and its enzymatic products are involved in neurotransmission and synaptic plasticity [9, 10] . Stimulation of glutamate receptors not only results in Ca 2+ influx essential for long-term potentiation (LTP) [11] but also activates PLA 2 . This leads to formation of arachidonic acid and lysophospholipids [12, 13] which increase vesicle exocytosis [14, 15] . PLA 2 facilitates neurotransmission in hippocampal neurons [16] whereas inhibition of PLA 2 decreases LTP [17, 18] .
sPLA 2 -IIA is localized in the CNS [6, 19] . Dense immunolabeling of sPLA 2 -IIA is observed in the rat brainstem and spinal cord, where the enzyme is present in a postsynaptic location in neurons [6] . sPLA 2 -IIA plays a role in nociception from the paw and orofacial region [20, 21] and may contribute to neuronal injury in acute and chronic neurodegenerative diseases. sPLA 2 -IIA activity and expression are upregulated after cerebral ischemia [22, 23] and spinal cord injury [24] . Enzyme expression is increased in Alzheimer's disease, especially in regions containing amyloid-␤ plaques [25] . The latter induces the expression of proinflammatory cytokines such as TNF-␣ and IL-1 ␤ , which in turn upregulate sPLA 2 -IIA [26, 27] . Treatment of cortical neurons with sPLA 2 -IIA induces release of arachidonic acid and apoptosis [28] . sPLA 2 could mediate neuronal death through ionotropic glutamate receptors [29] . The enzyme also increases Ca 2+ influx through L-type voltage-gated calcium channels [30] .
␣ -Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), kainate (KA) and N-methly-D -aspartate (NMDA) receptors are classified as ionotropic glutamate receptors [31] . AMPA receptors are composed of GluR1-4 subunits whilst KA receptors consist of GluR5-7 or KA1-2 subunits [32] [33] [34] . Many studies show that glutamate receptors mediate synaptic transmission and plasticity in the brain [33, 35, 36] . In addition, glutamate receptors regulate secretion of neuromodulators such as substance P from synaptosomes [37, 38] . There is also evidence that KA receptors can have metabotropic actions via G-protein signaling cascades linked to protein kinase C (PKC) [33, 36, 39] . sPLA 2 -IIA stimulates exocytosis and release of neurotransmitters from neurons [40] and could itself be released from synaptosomes upon potassium-induced depolarization [41] . However, to date, a possible relation between glutamate receptor activation and sPLA 2 -IIA exocytosis is unknown. In this study, we elucidated the differential effects of glutamate receptor agonists on vesicular exocytosis and release of sPLA 2 -IIA in human neuroblastoma SH-SY5Y cells.
Materials and Methods

Construction of the Rat Spinal sPLA 2 -IIA cDNAs and Expression Vectors
Total RNAs from the rat spinal cord was extracted and isolated using Trizol reagent (Invitrogen, USA), and purified using the RNeasy Mini Kit (Qiagen Inc., USA). The spinal cord was chosen as the tissue source for sPLA 2 -IIA mRNA since our recent study showed high relative expression of the enzyme in this organ [6] . The RNA was reverse transcribed using the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, USA) with the following conditions: 25 ° C for 10 min, 37 ° C for 120 min and 85 ° C for 5 s. The sPLA 2 -IIA enzyme includes a signal peptide [6, 42] . By using the SignalP 3.0 Server, the sequence of sPLA 2 -IIA without N -terminal signal peptide was determined to be from the 121st to 441st base pairs of sPLA 2 -IIA (NM_031598.3).
Two sets of primers were designed based on the sequence of rat sPLA 2 -IIA gene: (1) F1 5 -TGGATGAAGGTCCTCCT G TT-GCT-3 and B1 5 -TCAGCAACTGGGCGTCTTCCCTT-3 for insertion into the pcDNA3.1/CT-GFP-TOPO vector (Invitrogen) and (2) F2 5 -CAGTCTCGAGCGGATGAAGGTCCT CC TG TT-GCTA-3 and B2 5 -GTACGAATTCCTATCAGCAACT GGG-CGT-3 for insertion into the pIRES2-EGFP vector (BD Biosciences Clontech, Mountain View, Calif., USA). The primers for sPLA 2 -IIA without signal peptide sequence for insertion into the pcDNA3.1/CT-GFP-TOPO vector were: F1 5 -TGGATGA G CC-TTCTGGAGTTTGG-3 and B1 5 -TCAGCAACTGGGC GTCT T-CCCTT-3 . The PCR temperature profile was 95 ° C for 30 s followed by 33 cycles of 94 ° C for 1 min, 56 ° C for 1 min, 72 ° C for 1 min and a final extension step at 72 ° C for 10 min. PCR products were separated on agarose gel and the fragments containing the cDNA of either full-length sPLA 2 -IIA or sPLA 2 -IIA without signal peptide were extracted using the QIAquick Gel Extraction protocol (Qiagen). To obtain sPLA 2 -IIA-GFP fusion protein, cDNA inserts of sPLA 2 -IIA (sPLA 2 -IIA with or without signal peptide) were cloned into pcDNA3.1/CT-GFP-TOPO using the CT-GFP Fusion TOPO Expression kit (Invitrogen). Recombinant plasmid sPLA 2 -IIA-IRES-EGFP (full length sPLA 2 -IIA) was produced by cloning the cDNA insert for sPLA 2 -IIA with signal peptide, into pIRES2-EGFP at the sites of Xho I and Eco RI. Plasmids were purified using QIAprep Spin Miniprep Kit (Qiagen) and verified by DNA sequencing to confirm integrity and orientation.
Cell Culture and Generation of Stable Cell Lines
Human neuroblastoma SH-SY5Y cells (American Type Culture Collection, Rockville, Md., USA) were grown in Dulbecco's modified Eagle's medium (DMEM, Gibco, Rockville, Md., USA) supplemented with 2 m M L -glutamine, 1% penicillin/streptomycin and 10% heat-inactivated fetal bovine serum (Gibco). Cells were maintained at 37 ° C in a saturated humidity atmosphere containing 95% air and 5% CO 2 . In order to establish stable cell lines, FuGENE Transfection Reagent (Roche, Indianapolis, Ind., USA) was used. Specifically, after 70-80% confluence, cells were transfected with 1-2 g of recombinant expression vectors, sPLA 2 -IIA-GFP (sPLA 2 -IIA with or without signal peptide), or sPLA 2 -IIA-IRES-EGFP (sPLA 2 -IIA with signal peptide), or empty vector, followed by incubation of cells at 37 ° C for 2 days in culture medium. The transient cell lines were subcultured and grown in culture medium containing selection reagent (G418 sulfate, 500 g/ml; Invitrogen) for 10 days, with a change of medium every 2 days. Subsequently, transfected cells were transferred into a 96-well plate ensuring that only a single colony is present in each well, grown for another 2 weeks and subcultured into larger wells to obtain stable cell lines. Immunocytochemical Analyses SH-SY5Y cells stably expressing sPLA 2 -IIA-GFP (full-length sPLA 2 -IIA) were immunolabeled with synaptotagmin-1 or neuropeptide Y (NPY; Santa Cruz Biotech, Santa Cruz, Calif., USA) to determine possible colocalization of the enzyme with other vesicles markers. The cells were plated on glass cover slips and fixed with 4% formaldehyde for 10 min. They were then permeabilized with 0.1% Triton X-100 and blocked with 1.5% bovine albumin before overnight incubation with a mouse monoclonal antibody to synaptotagmin-1 (Synaptic Systems GmbH, Göttingen, Germany; diluted 1: 100) or a rabbit polyclonal antibody to NPY (diluted 1: 100). The cells were washed with PBS and incubated with donkey anti-mouse secondary antibody conjugated with Alexa Fluor 555 (Invitrogen) or goat anti-rabbit secondary antibody conjugated with Atto 647 NHS (Sigma-Aldrich, St. Louis, Mo., USA) for 1 h at room temperature. Cells were then washed with PBS and viewed using a LSM 510 Meta confocal laser scanning microscope (Carl Zeiss).
Total Internal Reflection Fluorescence Microscopy Analysis
Western Blot Analysis
SH-SY5Y cells stably expressing sPLA 2 -IIA were seeded in 75-cm 2 flasks (4 ! 10 5 cells/flask) and grown to confluence. Cells (5 ! 10 6 cells/ flask) were then washed 3 times with PBS and incubated in serum-free DMEM medium with or without test chemicals for 120 min at 37 ° C. The medium was then harvested and stored at -20 ° C. Cells were washed 3 times with ice-cold PBS and lysed using RIPA lysis buffer containing protease inhibitors (Santa Cruz Biotech). Protein concentrations in the collected medium or the cell lysates were determined using the Bio-Rad protein assay kit (Bio-Rad Laboratories, San Diego, Calif., USA). Protein samples were separated on 12% SDS polyacrylamide gels under reducing conditions and blotted onto nitrocellulose membranes using a Mini-Transblot apparatus (Bio-Rad). The membranes were blocked for 2 h with 5% nonfat milk in Tris-buffered salineTween (TBST) buffer (10 m M Tris, 150 m M NaCl and 0.1% Tween-20, pH 7.4) and incubated overnight with rabbit primary antibodies to GFP, GAPDH (1:200-400; Biovision, Mountain View, Calif., USA), or sPLA 2 -IIA (1: 5,000) in TBST, followed by washing 3 times with TBST buffer. The anti-sPLA 2 -IIA antibody was prepared by immunizing a rabbit with purified recombinant rat sPLA 2 -IIA as described earlier [43] . Membranes were incubated with horseradish peroxidase-conjugated anti-rabbit IgG (1: 5,000; Thermo Scientific, Rockford, Ill., USA) for 6 h at room temperature. The enzyme protein was visualized with optiCN detection kit and quantified with QualityOne software (Bio-Rad). Immunoblots of secreted proteins and GAPDH were obtained using the same sample sets. GAPDH served as an internal control. Unless otherwise stated, all chemicals were purchased from Sigma-Aldrich, Saint Louis, Mo., USA. UBP302 and AMPA were purchased from Tocris (Tocris Bioscience, Ellisville, Mo., USA).
Statistical Analysis
Results are reported as mean 8 SEM, and statistical significance was analyzed by one-way ANOVA with Bonferroni's post hoc test. p ! 0.05 was considered significant.
Results
sPLA 2 -IIA Proteins Are Packed into Fusion-Competent Vesicles
Individual secretory vesicles in the subplasmalemmal region and their fusion with the plasma membrane were visualized using the technique of TIRFM, which evanescently illuminates the thin region ( ! 200 nm) immediately adjacent to the cell membrane [44] . sPLA 2 -IIA protein (GFP-tagged full-length sPLA 2 -IIA) was found in vesicle-like structures, in human neuroblastoma SH-SY5Y cells stably expressing sPLA 2 -IIA-GFP ( fig. 1 a) . The vesicles undergo constant lateral (parallel to the plasma membrane) and vertical trafficking (vesicle transit between the inner cytosol to the subplasmalemmal region) ( fig. 1 c) . Spontaneous fusion events of sPLA 2 -IIA vesicles were frequently observed by TIRFM similar to those observed for secretory vesicles in neuroendocrine [44] [45] [46] . They appeared as an abrupt increase in fluorescence intensity due to rapid release of fluorescent molecules from a vesicle, followed by broadening and disappearance of fluorescence as the molecules diffuse away [47] ( fig. 1 d) . These observations suggest that sPLA 2 -IIA molecules are contained in fusion-competent vesicles which are released constitutively or upon stimulation. Confocal microscopy of SH-SY5Y cells expressing GFP-tagged fulllength sPLA 2 -IIA revealed a punctuate fluorescence pattern characteristic of secretory vesicles ( fig. 2 ) . We also examined possible colocalization of sPLA 2 -IIA with synaptotagmin-1, a Ca 2+ sensor localized in secretory vesicles [48] or NPY, a marker of large dense core vesicles [49] . sPLA 2 -IIA containing vesicles were found to be colocalized with synaptotagmin-1 ( fig. 2 a) , but not NPY ( fig. 2 b) .
KA Induces Vesicular Release of sPLA 2 -IIA
The effects of glutamate and its analogs on the exocytosis of sPLA 2 -IIA from SH-SY5Y cells stably transfected with sPLA 2 -IIA-GFP were examined by TIRFM. Increased number of fusion events of sPLA 2 -IIA vesicles was observed 30 min after application of 10 M KA ( fig. 3 a) . This is corroborated by the detection of increased sPLA 2 -IIA release (sPLA 2 -IIA-GFP, about 42 kDa) (p ! 0.05) after 2 h of incubation with 10 M of KA ( fig. 3 b) . This effect was dose dependent and observed after treatment with 100 n M to 10 M KA ( fig. 3 c) . Addition of AMPA (10 M , 2 h of incubation) also induced sPLA 2 -IIA secretion. However, no effect on sPLA 2 -IIA secretion or fusion frequency was detected after addition of 10 M of NMDA or glutamate ( fig. 3 a, b) .
Effect of CNQX on sPLA 2 -IIA Secretion 6-Cyano-7-nitroquinoxaline-2,3-dione (CNQX) is an inhibitor of AMPA receptors. As shown in figure 4 a, 20 M CNQX did not significantly suppress KA-induced vesicular exocytosis of sPLA 2 -IIA. CNQX, however, significantly inhibited AMPA-induced sPLA 2 secretion (p ! 0.05; fig. 4 
b).
KA-Induced sPLA 2 -IIA Secretion Occurs through the GluR5-Containing KA Receptor KA receptors include GluR5 or GluR6 subunits which have been localized pre-or postsynaptically and are involved in synaptic transmission and plasticity [36] . A GluR5-specific KA receptor antagonist UBP302 [S-1-(2-amino-2-car boxyethyl)-3-(2-carboxybenzyl) pyrimidine-2,4-dione] [50] or a GluR6-specific antagonist NS 102 (6,7,8,9-tetrahydro-5-nitro-1H-benz[g]indole-2,3-dione 3-oxime) [51] was used to determine whether the effect of KA on sPLA 2 -IIA secretion was mediated through the GluR5-or GluR6-containing receptors. 20 M UBP302 abolished KA-induced vesicular exocytosis and release of sPLA 2 -IIA (p ! 0.05; fig. 5 a, b) . On the other hand, NS 102 did not significantly suppress sPLA 2 -IIA secretion. These results indicate that KA-induced exocytosis and release of sPLA 2 -IIA in SH-SY5Y cells are mediated by receptors containing the GluR5 subunit.
KA-Induced sPLA 2 -IIA Secretion Is Ca
2+ Dependent The number of spontaneous fusion events was significantly reduced when extracellular Ca 2+ was depleted by the calcium chelator EGTA (2 m M ), or when the intracellular Ca 2+ pool was depleted by thapsigargin (1 M , 15 min pretreatment) [52] ( fig. 6 a) . In addition, 10 M KAinduced sPLA 2 -IIA secretion was suppressed when external or internal Ca 2+ was depleted ( fig. 6 a, b) . The results indicate that Ca 2+ is required for exocytosis of sPLA 2 -IIA in SH-SY5Y cells under basal conditions or after KA stimulation.
KA-Induced sPLA 2 -IIA Secretion Is PKC Dependent KA receptors especially those containing GluR5 could signal through a metabotropic action involving phospholipase C and activation of PKC [33, 36] . The latter is known to regulate exocytosis via phosphorylation of key proteins in the exocytotic cascade [53] . Bisindolylmaleimides (BIS, selective and potent inhibitors of PKC) were used to block PKC activity [54, 55] in SH-SY5Y cells to determine a possible role of PKC in spontaneous and KA-induced sPLA 2 -IIA secretion. Inhibition of PKC by either of the BIS compounds Ro-32-0432 (BIS-XI) [56] or Ro-31-8220 (BIS-IX) [57, 58] reduced the number of fusion events under basal and KA-stimulated conditions ( fig. 7 a) .
BIS compounds did not affect basal sPLA 2 -IIA release as detected by Western blots ( fig. 7 b) but significantly inhibited KA-induced sPLA 2 -IIA release. In addition 100 n M phorbol-12-myristate-13-acetate (PMA), a potent diacylglycerol (DAG) analog that activates PKC, induced exocytosis and release of sPLA 2 -IIA, while this effect was largely blunted in the presence of PKC inhibitor ( fig. 7 ) . These findings indicate a role of PKC in KA-induced exocytosis of sPLA 2 -IIA.
Signal Peptide Is Required for Vesicular Localization and Exocytosis of sPLA 2 -IIA
We next examined the role of signal peptide of sPLA 2 -IIA in vesicular localization and exocytosis using TIRFM. In contrast to the numerous vesicle-like structures in SH-SY5Y cells stably cloned with sPLA 2 -IIA-GFP (full-length sPLA 2 -IIA) ( fig. 1 a) , cells that stably expressed sPLA 2 -IIA without signaling peptide showed homogeneous green fluorescence without any visible vesicle-like structures ( fig. 8 a) .
Exocytosis was not observed in cells that stably expressed sPLA 2 -IIA without signal peptide ( fig. 8 b) and there was very little sPLA 2 -IIA in the culture medium of cells expressing sPLA 2 -IIA-GFP without signal peptide. Moreover, 10 M KA could no longer induce sPLA 2 -IIA secretion from these cells ( fig. 8 c) . These findings indicate that the signal sequence of sPLA 2 -IIA is essential for its vesicular localization and exocytosis.
KA-Induced sPLA 2 -IIA Secretion
The effects of glutamate and its analogs on the secretion of sPLA 2 -IIA from SH-SY5Y cells stably transfected with sPLA 2 -IIA-IRES-EGFP vector were analyzed by Western blots. Cells were transfected with sPLA 2 -IIA-IRES-EGFP vector which produces separate expression of sPLA 2 -IIA and EGFP, and sPLA 2 -IIA released into the medium was directly detected with a specific antibody to the enzyme. As shown in figure 9 a, 10 M KA stimulated sPLA 2 -IIA secretion (sPLA 2 -IIA, about 15 kDa; p ! 0.05). However, no significant enhancement of sPLA 2 -IIA secretion was found after addition of NMDA, AMPA or low doses of glutamate itself. Very low levels of EGFP (EGFP, about 27 kDa) were detected in the culture medium and no increase in EGFP was detected after addition of glutamate analogs ( fig. 9b) , consistent with regulated secretion of sPLA 2 -IIA but not EGFP upon stimulation by KA.
Discussion
The present study was carried out to elucidate the factors that result in sPLA 2 exocytosis in neurons. sPLA 2 -IIA was stably expressed as a GFP fusion protein in SH-SY5Y cells which has morphological and biochemical characteristics and proteomic expression of mature neurons [59, 60] . sPLA 2 -IIA was found to be contained in fusion-competent vesicles in these cells and released through exocytosis, even under basal conditions. In contrast, cells that stably express sPLA 2 -IIA without signal peptide showed homogeneous green fluorescence without visible vesicle-like structures and exocytosis. These results are striking as they demonstrate that sPLA 2 -IIA is packaged in secretory vesicles and released, similar to several of the neuropeptide modulators such as substance P and NPY which are contained in granules at nerve endings [61, 62] . In addition, immunocytochemical analyses showed that sPLA 2 -IIA is colocalized with a marker of secretory vesicles, synaptotagmin-1 [48] . The latter is a calcium sensor important for synaptic vesicle release in axons and vesicular exocytosis in dendrites [63, 64] . Several studies have reported sPLA 2 in neurons of the CNS [5, 6] . We therefore sought to determine whether sPLA 2 could be released from cells in response to excitatory, glutamatergic stimulation. This was carried out on SH-SY5Y cells, which have been shown to express NMDA, AMPA and KA receptors [65] [66] [67] including the GluR5 subunit [59] (see online supplementary figure 1, www. karger.com/doi/10.1159/000330414). Besides direct visualization and quantitation of exocytotic events by TIRFM ( fig. 2 b) , Western blot analyses were carried out to detect secretion of sPLA 2 -IIA-EGFP fusion protein into the culture media. The dose of AMPA, KA, NMDA or glutamate used in these experiments was 10 M , which is less than the toxic doses of 40 M for AMPA [68] ; 25-200 M for KA [67, 69] ; 0.1-5 m M for NMDA [69, 70] , and 2-100 m M for glutamate [71, 72] for human neuroblastoma SH-SY5Y cells. External application of KA or AMPA resulted in increased exocytosis and release of sPLA 2 -IIA whereas NMDA did not show any significant effect ( fig. 2 ). In contrast, no exocytosis was observed after AMPA or KA stimulation in cells expressing sPLA 2 -IIA without signal peptide ( fig. 8 a, b) . These observations confirm the requirement of this peptide in sPLA 2 vesicular localization and exocytosis, and importantly, demonstrate that AMPA-or KA-induced exocytosis of sPLA 2 -IIA was not the result of general toxicity or lysis of cells, due to excessive glutamatergic stimulation under our experimental conditions ( fig. 9 a) . Together, the results indicate that AMPA and KA receptors are important for regulated secretion of sPLA 2 -IIA from neuron-like cells.
The relative contributions of AMPA and KA receptors to sPLA 2 -IIA exocytosis were verified using antagonists to these receptors. Cells that express sPLA 2 -IIA-GFP fusion protein were treated with AMPA or KA in the presence of receptor antagonists. AMPA receptors are composed of GluR1-4 subunits, whilst KA receptors consist of GluR5-7 and KA1-2 subunits [32] [33] [34] . These subunits probably exist as heteromers in vivo [73] . KA can activate AMPA receptors, and AMPA can bind to KA receptors, suggesting overlapping binding affinity for AMPA and KA receptors [74] . CNQX is an antagonist at AMPA receptors but has some activity against KA receptors. 10-20 M CNQX blocks KA receptor-mediated excitatory postsynaptic currents by 40-80% [75] . Addition of CNQX partially blocked AMPA-but not KA-induced sPLA 2 -IIA exocytosis. This is expected, since CNQX acts mainly at AMPA receptors. UBP 302 and NS102 are selective antagonists of GluR5 and GluR6 KA receptor subunits, respectively, at 10 M [76, 77] . Application of UBP 302 (a GluR5 subunit-specific KA receptor antagonist) abolished KA-induced sPLA 2 -IIA secretion, whereas addition of NS102 (GluR6 subunit-specific KA receptor antagonist) did not show such inhibition. These observations indicate that AMPA and KA receptors are important for stimulating exocytosis of sPLA 2 -IIA although the majority of the effect appears to be mediated by GluR5 receptors.
The above experiments were carried out on SH-SY5Y cells that stably express sPLA 2 -IIA-GFP fusion protein.
As controls against any unforeseen effects of the GFP tag on sPLA 2 -IIA enzyme function, we conducted further studies using cell lines that express full-length sPLA 2 -IIA, independent of the GFP tag. This was carried out using the sPLA 2 -IIA-IRES-EGFP vector, i.e. sPLA 2 -IIA and EGFP were cotransfected in the same cell using a single vector but not as a fusion protein. Stable cell lines expressing sPLA 2 -IIA were selected based on the EGFP fluorescence label, and enzyme release from these cells was detected using an antibody to sPLA 2 -IIA. The findings confirm that sPLA 2 -IIA protein is released from the SH-SY5Y cells by KA stimulation.
Possible mechanisms of KA action on sPLA 2 -IIA release were also elucidated. AMPA, KA and NMDA receptors are typically described as ligand-gated ionotropic glutamate receptors [31] . Activation of these receptors increases free intracellular Ca 2+ in neurons and SH-SY5Y cells [65] . Significantly reduced spontaneous or KA-induced fusion events and release of sPLA 2 -IIA were detected in cells treated with the Ca 2+ chelator EGTA or after depletion of intracellular calcium by thapsigargin, consistent with a requirement for Ca 2+ in vesicular exocytosis [78] . Exocytosis was also induced by high potassium depolarization of cells (online suppl. fig. 2 ). In several CNS regions including the hippocampus and spinal cord, reports have indicated that KA receptors could be metabotropically coupled with G-protein signaling cascades that involve the activation of phospholipase C generation of DAG and subsequent activation of PKC [33, 36, 39] . We observed that KA-induced sPLA 2 -IIA exocytosis was inhibited by a PKC inhibitor, whereas acti vation of PKC by PMA triggered vesicular secretion of sPLA 2 -IIA. This may involve several proteins implicated in exocytosis which are PKC substrates, including SNAP-25 (synaptosome-associated protein) and Munc-18 (essential component of the synaptic vesicle fusion protein complex) which potentiate vesicle recruitment and sensitize vesicle release [53] . Moreover GAP-43, a specific PKC substrate that is important in priming of exocytosis [79] is upregulated in hippocampal granule neurons treated with KA [80, 81] . PKC may in turn phosphorylate KA receptors, leading to changes in channel conductance [82, 83] . Together, the results indicate PKC-dependent KA-induced vesicular exocytosis and release of sPLA 2 -IIA.
The link between glutamate receptors and sPLA 2 -IIA exocytosis may be functionally important. Since sPLA 2 is present in the brain under basal conditions, this could implicate a link between glutamate signaling, sPLA 2 secretion, and neurotransmitter exocytosis. sPLA 2 is detected in different parts of the brain including the hippocampus [6, 7] and is involved in synaptic transmission and LTP [84, 85] . KA receptor subunits GluR5 and KA2 also form the predominant heterometic pair in postsynaptic KA receptors of the hippocampus [33] . KA-mediated excitatory postsynaptic currents in the hippocampus are generated mainly by GluR5-containing KA receptors [77] . In addition, postsynaptic KA-mediated excitatory postsynaptic current onto second-order neurons in the spinal cord has been reported [86] . Electron microscopy reveals that the majority of KA receptors, GluR5, 6, 7, are postsynaptic to substance P-containing axon terminals in the trigeminal dorsal horn [87] . Together with electron-microscopic observations that sPLA 2 -IIA is localized in a postsynaptic location in the spinal cord [6] , we hypothesize that release of glutamate at a glutamatergic synapse may activate GluR5-containing KA receptors to induce sPLA 2 -IIA exocytosis from storage vesicles in dendrites. Previous electrophysiological study indicates that sPLA 2 -IIA could stimulate the release of neurotransmitters from PC12 neuroendocrine cells and cultured neurons [40] ; hence, it is conceivable that sPLA 2 -IIA could diffuse across the synaptic cleft to induce glutamate release from axon terminals. In this scenario, sPLA 2 -IIA is released from dendrites as a result of AMPA or KA receptor activation, and acts as a retrograde signal to amplify neurotransmission. Our findings of high-level expression of sPLA 2 -IIA in the dorsal horn and spinal trigeminal nucleus [6] and the present link with KA receptors are consistent with a role of these receptors and sPLA 2 in nociceptive transmission. Intraperitoneal injection of the KA receptor antagonist SYM 2081 reduced mechanical allodynia and thermal hyperalgesia after chronic-constriction nerve injury [88] or freeze injury [89] . The GluR5 antagonist LY 382884 produced antinociceptive responses to formalin in rats [90] . Moreover, responses to capsaicin or inflammatory pain were significantly reduced in mice lacking GluR5 but not GluR6 subunits [91] . Similarly, intrathecal administration of the sPLA 2 inhibitor, LY311727 reduced inflammatory hyperalgesia in rats [20] , and intracerebroventricular injection of the sPLA 2 inhibitor 12-episcalaradial decreased nociceptive responses after facial carrageenan injection in mice [21] .
In conclusion, the present findings show that sPLA 2 -IIA enzymes are packed into fusion-competent vesicles in human neuroblastoma SH-SY5Y cells and are released through exocytosis by glutamate analogs. Together, these results provide evidence of a link between glutamate receptors and sPLA 2 -regulated secretion in neurons that may play an important role in the normal physiology of the CNS, nociception and neurodegenerative diseases.
